This remote rigorous three-day program is ideal for basic research and translational biology scientists who are looking for a balanced theoretical vs. laboratory introduction to CRISPR toolkit. Taught by active [….]
The Discovery Labs’ 2.4 million square foot site in King of Prussia, PA provides all the necessary ingredients to accelerate speed to market for cell and gene therapy innovators. The Center for Breakthrough Medicines is a cell and gene therapy contract development and manufacturing organization (CDMO) for plasmid DNA, viral vectors, and cellular therapy products and is located on-site.
Duchenne Muscular Dystrophy is a severe degenerative muscle disease that impacts about one in 5,000 boys per year across the globe. The disease causes a progressive loss of muscle strength attributable to a loss of a protein called dystrophin, which normally protects muscle fibers from breaking down.
$7.50 per share
Dr. Mark DeWitt, a leading industry expert, shares his secrets on success with the development of a CRISPR/Cas9-based strategy
Correction of the Sickle Cell Disease Mutation with CRISPR/Cas9 Description Sickle Cell Disease (SCD), one of the world’s most common genetic disorders, causes anemia and progressive multiorgan damage that typically [….]
Mike O’Mara has more than 27 years of experience in biopharmaceutical contract manufacturing encompassing microbial, mammalian, and cell/Gene therapy manufacturing processes ranging from Preclinical/Phase I through Commercial.
Why Advanced Biomanufacturing in Maryland is a Thriving Industry These Four Industry-leading BioManufacturing Companies Represent Thousands of Jobs in Maryland and Are Shaping the Future of Medicine A burgeoning cell [….]
Bryan Poltilove is a Managing Director focused on guiding BroadOak’s growth capital investing strategy and advising portfolio companies in the life sciences and cell and gene therapy sectors.
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability June 18, 2020 Company acquires property adjacent to its Canton, Massachusetts live viral [….]
After decades of work, gene therapies promise a revolution in medicine. How can society figure out how to afford them? Join STAT reporters along with selected experts in the field [….]